Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol/Gilead joint venture targets 2005 filing for fixed-dose HIV combo. A new brand name for the fixed-dose combination of Bristol’s Sustiva and Gilead’s Truvada is expected. Firms will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products”